Desmoines News Desk

Retinitis Pigmentosa Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies

 Breaking News
  • No posts were found

Retinitis Pigmentosa Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies

January 25
07:52 2023
Retinitis Pigmentosa Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 45+ key pharma and biotech companies are working on 45+ pipeline drugs in the Retinitis Pigmentosa therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA) and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Retinitis Pigmentosa Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Retinitis Pigmentosa Market. 

The Retinitis Pigmentosa Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Retinitis Pigmentosa Pipeline Analysis

Retinitis Pigmentosa Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Retinitis Pigmentosa and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Retinitis Pigmentosa market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Retinitis Pigmentosa – Emerging Therapies Mechanism of Action (MOA)

  • Gene transference

  • Cell replacements

  • Integrin inhibitors

  • Cell replacements; Nerve growth factor modulators

 

Retinitis Pigmentosa – Route of Administration 

Retinitis Pigmentosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as –

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

 

Molecule Type

Products have been categorized under various Molecule types, such as – 

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

 

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

 

Learn How the Ongoing Clinical & Commercial Activities will Affect the Retinitis Pigmentosa Therapeutic Segment @

https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight

Retinitis Pigmentosa Therapeutics Landscape

Currently, there is no therapy that can stop the evolution of pigmentary retinopathies or restore vision. Management of retinitis pigmentosa includes dietary supplements, ozone therapy, surgery, etc. Gene therapy-based treatments are under research focus for the treatment of Retinitis pigmentosa.

There are approx. 45+ key companies developing therapies for Retinitis Pigmentosa. Currently, Biogen is leading the therapeutics domain with its Retinitis Pigmentosa drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Retinitis Pigmentosa Therapeutics Market Include:

  • Allegro Ophthalmics

  • Allergan

  • Biogen

  • Dompé Farmaceutici

  • Editas Medicine

  • Horama

  • ID Pharma

  • Ionis Pharmaceuticals

  • jCyte

  • MeiraGTx

  • Nacuity Pharmaceuticals

  • Neurotech

  • Nightstar Therapeutics/Biogen

  • Novartis Pharmaceuticals

  • OiDE OptoEye

  • ReNeuron

  • ReNeuron

  • Sanofi (Terminated)

  • SparingVision

 And Many Others

Retinitis Pigmentosa Drugs Covered in the Report Include:

  • BIIB-112: Biogen

  • QR 1123 (formerly ISIS RHO 2.5Rx): Ionis Pharmaceuticals

  • ALG-1001: Allegro Ophthalmics/Hanmi Pharmaceuticals

  • NPI 001: Nacuity Pharmaceuticals

  • AAV8- RPGR/BIIB1121: Nightstar Therapeutics/Biogen

  • ReN 003: ReNeuron

  • jCell: jCyte

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Retinitis Pigmentosa Current Treatment Patterns

4. Retinitis Pigmentosa – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Retinitis Pigmentosa Late Stage Products (Phase-III)

7. Retinitis Pigmentosa Mid-Stage Products (Phase-II)

8. Retinitis Pigmentosa Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Retinitis Pigmentosa Discontinued Products

13. Retinitis Pigmentosa Product Profiles

14. Key Companies in the Retinitis Pigmentosa Market

15. Key Products in the Retinitis Pigmentosa Therapeutics Segment

16. Dormant and Discontinued Products

17. Retinitis Pigmentosa Unmet Needs

18. Retinitis Pigmentosa Future Perspectives

19. Retinitis Pigmentosa Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight

 

Other Trending Healthcare Reports By DelveInsight

Hematological Cancer (Blood Cancer) Therapeutics Market

The global Hematological Cancer (Blood Cancer) Therapeutics Market was valued at USD 56.59 billion in 2021, growing at a CAGR of 10.14% during the forecast period from 2022 to 2027 to reach USD 100.80 billion by 2027. The market is witnessing positive growth owing to various factors such as rising blood cancer cases due to gene or DNA mutation, exposure to carcinogenic substances, and smoking, among others. Additionally, the increasing prevalence of lifestyle disorders such as diabetes, hypertension, obesity, hyperlipidemia, and others due to sedentary lifestyles & unhealthy eating are also contributing to the market growth.

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories